Boston, MA 03/06/2014 (wallstreetpr) – ANI Pharmaceuticals Inc (NASDAQ:ANIP) is now a $359.09 million market capped biotech company, thanks to the nice run in the stock. Shares of the company were last seen changing hands at $37.60. The stock also managed to attain a new one-year high price level at $38.21, shuttering previous numbers mercilessly.
The excitement around ANI Pharmaceuticals Inc (NASDAQ:ANIP) can be traced back to February 18, when the company reported widely strong earnings. Then the attractive pricing of its secondary offering is also strengthening confidence in the stock. Yet, while there can be debate about whether the stock will maintain its current upward trend for the longest possible duration, there is no question that the future is bright for this biotech stock.
Earnings Speak Louder Than Words
Look, the recently announced earnings figures speak for themselves. In fact, they are testimony to proper execution at ANI Pharmaceuticals Inc (NASDAQ:ANIP). While several biotech stocks have produced significant gains, ANIP came up with amazing results which highlight underlying strength in the company. The fourth quarter revenue was reported at $10.5 million, but that may seem like ordinary figure until you realize that it was a 98 percent grow year-over-year.
The company earned net income of $3.4 million, yet over the same quarter in the prior year, the column was in loss of $3.99 million. By most measures, the earnings were extremely strong and encouraging.
Path paved for future growth
ANI Pharmaceuticals Inc (NASDAQ:ANIP) has already made important steps to ensure that it remains in growth position into the future. The company late last year offered $12.5 million to Teva Pharmaceuticals to acquire 31 of its generic drug products. The market of the acquired generic drugs is estimated to be about $860 million. Thus, this important move should translate into revenue growth going forward.
Talk about revenue growth and ANI Pharmaceuticals Inc (NASDAQ:ANIP) has been growing this column very fast. In 2010, the company had revenue of $8 million and that has increased to $30 million.
Investor Takeaway
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reveals interesting and encouraging prospects. The stock and earnings have the room to continue growing. Regardless of the share dilution that will result from the secondary offering, there is greater strength in the stock than the secondary offering can dilute.
